Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS, expectations were $8.62. Operator: Welcome to the Regeneron ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

The S&P 500 advanced 0.6% on Tuesday, April 29, notching a sixth straight winning session. The White House signaled it would ...

Stocks closed higher Tuesday to extend a week-long rally as investors digested a flurry of earnings reports from major ...

The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).

Forté Sports Medicine and Orthopedics has expanded orthopedic services and care in Central Indiana. Five orthopedic surgeons ...

Dr. Google is often on call for worried patients, but it may not give the best advice. Doctors say internet searches for ...